Added 1 month ago Drug news
Merck Inc., has announced that the FDA has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of patients with...
Added 4 months ago Drug news
Merck announced that the FDA has accepted a new supplemental Biologics License Application (sBLA) and granted Priority Review for Keytruda...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries.
Added 6 years ago
Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival.
Added 5 months ago
Nerve Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: a Systematic Review and Meta-Analysis.
Few studies investigated the efficacy and safety of nerve sparing approach via minimally invasive surgery for the treatment of cervical cancer. We aimed to review the current evidence comparing nerve sparing minimally invasive...
Added 7 months ago
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study.
Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.
Added 10 months ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.